Get the Stockscreener App
17.56
10.30%
1.64
After Hours:
17.35
-0.21
-1.20%
Dyne Therapeutics Inc stock is traded at $17.56, with a volume of 1.93M.
It is up +10.30% in the last 24 hours and down -12.29% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$15.92
Open:
$16.18
24h Volume:
1.93M
Relative Volume:
0.96
Market Cap:
$2.90B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-4.9557
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
-4.77%
1M Performance:
-12.29%
6M Performance:
-12.72%
1Y Performance:
+42.30%
1-Day Range:
$16.05
$17.64
1-Week Range:
$15.87
$18.84
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.56 | 2.73B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - Yahoo Finance UK
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
MSN Money - MSN
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,448 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares - MarketBeat
Dyne therapeutics CFO Lucera sells $26,585 in company stock By Investing.com - Investing.com Canada
Breakthrough Findings from Dyne Therapeutics (DYN) Enhance Marke - GuruFocus
Dyne therapeutics CFO Lucera sells $26,585 in company stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU taxes - Stock Titan
Dyne Therapeutics (DYN) CFO logs automatic 1,448-share tax-related sale - Stock Titan
Dyne Therapeutics (DYN) CEO’s 3,311-share sale is automatic tax withholding - Stock Titan
Lifesci Capital Issues Optimistic Outlook for DYN Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings - MarketBeat
Dyne Therapeutics (DYN) upgraded to buy: Here's what you should know - MSN
DYN Maintained by Bernstein -- Price Target Raised to $24.00 - GuruFocus
Form 144 filed on restricted stock units for DYN (NASDAQ: DYN) - Stock Titan
DYN (Nasdaq) insider resale of 5,727 shares; 4,062 RSUs granted - Stock Titan
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Clinical-stage Dyne Therapeutics lines up three healthcare investor events - Stock Titan
Responsive Playbooks and the DYN Inflection - Stock Traders Daily
Dyne Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
DYN SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Impact of FDA Leadership Changes on Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics: Runway To Fund Operations Into 1Qf 2028 >DYN - Moomoo
Dyne Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Dyne Therapeutics (DYN) Advances Towards Z-Rostudirsen Launch in DMD - GuruFocus
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - sharewise.com
Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results - MarketBeat
Dyne Therapeutics Q1 Net Loss Narrows - Moomoo
Dyne Therapeutics Reports Positive Q1 2026 Results: Advancing DMD & DM1 Programs Toward FDA Approval and Commercial Launch - Minichart
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Investing News Network
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kerr Douglas | Chief Medical Officer |
May 13 '26 |
Sale |
18.36 |
1,564 |
28,715 |
170,042 |
| Lucera Erick | Chief Financial Officer |
May 13 '26 |
Sale |
18.36 |
1,448 |
26,585 |
123,925 |
| Cox John | CEO & President |
May 13 '26 |
Sale |
18.36 |
3,311 |
60,790 |
370,834 |
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):